Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 68Burkitt Lymphoma 17Precursor Cell Lymphoblastic Leukemia-Lymphoma 16Leukemia, Biphenotypic, Acute 14Myelodysplastic Syndromes 12Leukemia 8Myeloproliferative Disorders 7Lymphoma, Mantle-Cell 7Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 6Recurrence 4Lymphoma, Non-Hodgkin 4Lymphoma 4Leukemia, Myelomonocytic, Chronic 4Blast Crisis 4Sarcoma, Myeloid 3Leukemia, Monocytic, Acute 3Down Syndrome 3Lymphoma, T-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Leukemia, Myelomonocytic, Juvenile 2Leukemia, Myelomonocytic, Acute 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Myeloid 2Hodgkin Disease 2Hematologic Neoplasms 2Anemia, Refractory, with Excess of Blasts 2Thrombocythemia, Essential 1Targeted Therapy 1

Interventions

Cyclophosphamide 3Vincristine 2Prednisone 2Etoposide 2Doxorubicin 2tazemetostat 1pembrolizumab 1fludarabine 1etoposide phosphate 1duvelisib 1Prednisolone 1Melphalan 1Cytarabine 1Carmustine 1Azacitidine 110-propargyl-10-deazaaminopterin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Enteropathy-Associated T-Cell Lymphoma × Cytarabine × 90 days × Clear all
NCT06692452 2026-04-01

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

Dana-Farber Cancer Institute

Phase 2 Withdrawn
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, T-Cell, Peripheral, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡